. Author manuscript; available in PMC: 2024 Apr 1.

Published in final edited form as: Eur Respir J. 2023 Apr 1;61(4):2102861. doi: 10.1183/13993003.02861-2021

Table 1:

Participant demographics

	CF (n=56)	Non-CF (n=92)	P value
Age (years)	28.6 ± 13.4	37.0 ± 9.8	0.0001
Female	41.1%	51.1%	0.24
Caucasian	94.6%	91.3%	0.46
CFTR genotype
Homozygous F508del (n=26)	46.4%	---
Heterozygous F508del (n=29)	51.2%	---
Baseline BMI (mean)	22.6 ± 4.7	---
Prior CFTR modulator	50.0%
Baseline FEV₁ (% predicted)	65.5 ± 25.3	---
Hospitalizations 1 year prior to ETI initiation	0.6 ± 1.4	---
Oral antibiotic courses 1 year prior to ETI initiation	2.4 ± 2.3	---

P values determined by unpaired t-test for continuous variables or Fisher’s Exact test for categorical variables.